This post will be closed automatically in 2026-08-18 03:11
Reward60points
Edited by Almarfadi at 2026-8-15 03:11
journalㄩAnnals of Internal Medicine
AuthorsㄩMalahat Khalili; Faraidoon Haghdoost; Amin Liaghatdar; Kian Torabiardakani; Fatemeh Mahdian; Tal Levit; Sara Moradi; Ehsan Hedayati; Farzaneh Ahmadi; Sahar Khademioore; Tariq Atkin-Jones; Ahmad Sofi-Mahmudi; Vivek Patil; Fatemeh Mirzayeh Fashami; Soheil Mehmandoost; Harjind S. Kahlon; Rachel J. Couban; Kameshwar Prasad; Seyed-Mohammad Fereshtehnejad; Norman Buckley; Jason W. Busse; Behnam Sadeghirad
Published dateㄩ2026-6-
DOIㄩ10.7326/annals-25-02221
PDF linkㄩhttps://www.acpjournals.org/doi/pdf/10.7326/ANNALS-25-02221
Article linkㄩhttps://doi.org/10.7326/annals-25-02221
Article SourceㄩAmerican College of Physicians﹝
Remarkㄩ |
50
Apixaban Is Effective and Safe in Reducing Venous Thromboembolism (VTE) in Obese Patients with Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (ALL/LL) Prevapix-ALL/Children's Oncology Group ACCL1333 Trial
